pyrimidine has been researched along with fludarabine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernardi, P; Cabrelle, A; Cesura, AM; Colonna, R; Costantini, P; Gambalunga, A; Milanesi, E; Petronilli, V; Pinard, E; Semenzato, G | 1 |
| Almasan, A; Erzurum, SC; Hill, BT; Janocha, AJ; Sharma, A; Smith, MR | 1 |
2 other study(ies) available for pyrimidine and fludarabine
| Article | Year |
|---|---|
The mitochondrial effects of small organic ligands of BCL-2: sensitization of BCL-2-overexpressing cells to apoptosis by a pyrimidine-2,4,6-trione derivative.
Topics: Alkaloids; Animals; Antineoplastic Agents; Apoptosis; Barbiturates; bcl-2-Associated X Protein; Benzophenanthridines; Benzopyrans; Caspase 9; Caspases; Cell Line; Cell Line, Tumor; Cell Survival; Chlorambucil; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Enzyme Activation; HeLa Cells; Humans; Ligands; Membrane Potentials; Microscopy, Fluorescence; Mitochondria; Phenanthridines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Rats; Rats, Wistar; RNA, Small Interfering; Staurosporine; Time Factors; Vidarabine | 2006 |
Targeting mTORC1-mediated metabolic addiction overcomes fludarabine resistance in malignant B cells.
Topics: B-Lymphocytes; Cell Line, Tumor; Drug Resistance, Neoplasm; Glycolysis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Oxidative Phosphorylation; Pyrimidines; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; TOR Serine-Threonine Kinases; Vidarabine | 2014 |